Continuous hyperfractionated accelerated radiotherapy in the treatment of high-grade astrocytomas

Bese N., Uzel O., Turkan S., Okkan S.

RADIOTHERAPY AND ONCOLOGY, vol.47, no.2, pp.197-200, 1998 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 47 Issue: 2
  • Publication Date: 1998
  • Doi Number: 10.1016/s0167-8140(97)00233-8
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.197-200
  • Istanbul University Affiliated: No


Between May 1993 and January 1995, 36 patients with high-grade astrocytomas were treated with 1.05 Gy continuous hyperfractionated accelerated radiotherapy three times daily to a total target dose of 59.85 Gy in 19 days with 6-h intervals. The median age of the patients was 51 years and the median follow-up was 58 weeks. The median survival rate was 58 weeks and the cumulative survival rare was 22% at 2 years, No severe toxicity occurred in patients treated with this fractionation scheme. These results suggest that continuous hyperfractionated accelerated radiotherapy is an altered fractionation schedule for: high-grade astrocytomas with tolerable acute toxicity and survival rates comparable to conventional fractionation and to other altered fractionation schedules. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.